Norwegian and foreign pharmaceutical companies that develop, produce, sell or market medications and pharmacological substances in Norway can be members of the association. LMI has 64 member organizations.
The 64 member companies in LMI have just under 4,000 employees in Norway and represent over 80 per cent of pharmaceutical sales. These are researchers, doctors, nurses, pharmacists, midwives, physiotherapists, biologists, health economists, engineers and a number of other professions. There are dedicated, skilled people who are passionate about their job, and who want to contribute to developing innovations that benefit patients and society. By innovations we mean, among other things, medicines, diagnostic tools and other health solutions for both humans and animals.
The association aims to protect the professional interests of its members where the pharmaceutical industry is concerned. Good framework agreements will provide Norwegian patients with access to safe essential medications to improve the health, well-being and quality of life for the Norwegian population. LMI plays a key political role in setting policies regarding the industry and also contributes by making the pharmaceutical industry’s contributions and achievement visible within the community.
LMI is an innovative trade organization that tries to influence commercial, nutritional and health policies and national visions on behalf of its member companies.
We in LMI believe it is essential to ensure a thorough assessment whether medicines are worth the money. But today’s process is too complicated and time consuming. In this video we explain what takes time: